Background--Women are at greater risk of developing pulmonary arterial hypertension, with estrogen and its downstream metabolites playing a potential role in the pathogenesis of the disease. Hypoxia-inducible factor-1-a (HIF1a) is a pro-proliferative mediator and may be involved in the development of human pulmonary arterial hypertension. The estrogen metabolite 2-methoxyestradiol (2ME2) has antiproliferative properties and is also an inhibitor of HIF1a. Here, we examine sex differences in HIF1a signaling in the rat and human pulmonary circulation and determine if 2ME2 can inhibit HIF1a in vivo and in vitro.
P ulmonary arterial hypertension (PAH) is a progressive disease characterized by pulmonary arterial tone dysfunction and hyperproliferation of pulmonary arterial smooth muscle cells (PASMCs). Women have a greater risk of developing PAH, with registries reporting the female-to-male ratio as high as 4:1.
1,2 The role of estrogen (E2) and estrogen metabolism in the development of PAH has been studied extensively. Indeed, estrogen and its downstream metabolite 16a-hydroxyestrone have been demonstrated to be involved in pro-proliferative responses in PASMCs and may be involved in the development of the human disease. [3] [4] [5] [6] [7] [8] Studies have also suggested a potential protective role for estrogen metabolites such as 2-hydroxyestradiol, 4-hydroxyestradiol, and 2-methoxyestradiol (2ME2). These can inhibit smooth muscle cellular proliferation and/or reverse experimental pulmonary hypertension (PH). 5, 9, 10 2ME2 is perhaps the best studied of these metabolites and has been shown to reverse PH in the bleomycin and monocrotaline rat models. 9, 11, 12 However, the mechanism as to how 2ME2 mediates this protective effect in the pulmonary system is unknown. 2ME2 has also been postulated to be beneficial in other hyperproliferative disease states such as cancer. Here, 2ME2 may arrest abnormal cellular growth and migration by disruption of the cytoskeletal network through depolymerization and disorganization of a-tubulin. 13, 14 This, in turn, has been shown to have a detrimental effect on hypoxia-inducible factor-1-a (HIF1a) stability and function. 13 HIF1a is a crucial mediator of many cellular functions. Under normoxic conditions, HIF1a is hydroxylated through the prolyl hydroxylases (PHDs). Hydroxylated HIF1a is then recognized by the Von HippelLindau tumor suppressor protein, which tags the hydroxylated HIF1a for proteosomal degradation through the E3 ubiquitinligase system. 15 However, under conditions of reducedoxygen tension, the PHDs become inhibited and HIF1a stabilizes within the cell where it can then translocate to the nucleus and interact with its binding partners HIF1b and the hypoxic response element to regulate transcription of many genes. 15, 16 HIF1a is further regulated by the asparaginal hydroxylase factor inhibiting HIF (FIH), which hydroxylates HIF1a and blocks association of HIF1a with its transcriptional coactivators. 17 HIF1a has also been implicated in the development of PAH, with increased protein expression observed in distal pulmonary arteries of idiopathic PAH patients. 18 Furthermore, increased activity of HIF1a is associated with an increase in mitogenic and angiogenic genes such as hexokinase 2 (HK2) and vascular endothelial cell growth factor A. [18] [19] [20] To date, there have been limited studies assessing sex differences in HIF1a signaling in the pulmonary circulation. Our hypothesis was that there are sex differences in HIF1a signaling in human PASMCs (hPASMCs) and that HIF1a signaling plays a role in the in vivo effects of 2ME2 in the rat hypoxic model of pulmonary hypertension. We also assessed the molecular mechanisms behind the effects of 2ME2 in both human and rat PASMCs.
Methods
Data within this paper can be found on the University of Glasgow approved data repository (http://www.gla.ac.uk/se rvices/datamanagement/lookingafteryourdata/preservation/ repositories). An expanded methods section is available in Data S1. 
Animal Studies

Hemodynamic Measurements
Right ventricular systolic pressure (RVSP) measurements and associated parameters were recorded using a Miller SPR-869 catheter and analyzed using the corresponding software (LabChart Pro version 8, ADInstruments; Dunedin, New Zealand) as described previously and in Data S1. 3 
Right Ventricular Hypertrophy
To assess right ventricular hypertrophy, the right ventricular free wall was removed and weighed. This was then expressed as a ratio to the left ventricular wall plus septum weight.
Culture and Isolation of PASMCs
Unless otherwise stated, female and male hPASMCs were isolated from pulmonary arteries of non-PAH patients undergoing a pneumonectomy procedure (0.3-1 mm diameter) from distal portions of macroscopically normal lung tissue as described previously (http://www.gla.ac.uk/services/data
Clinical Perspective
What Is New?
• We have shown that hypoxia-inducible factor-1-a (HIF1a) protein expression is increased in female pulmonary artery smooth muscle cells (PASMCs) compared with male PASMCs and that the regulatory mechanisms that govern HIF1a expression and activity are lower in female PASMCs.
• This study has also shown that 2-methoxyestradiol is an effective inhibitor of HIF1a, both in vivo and in vitro.
• We have also demonstrated that 2-methoxyestradiol can affect PASMC microtubule structure, which may further contribute to its antiproliferative properties.
What Are the Clinical Implications?
• Increased HIF1a expression and activity is associated with many hyperproliferative disease states, including pulmonary arterial hypertension.
• Women are at greater risk of developing pulmonary arterial hypertension; therefore, increased basal expression of HIF1a may predispose female PASMCs to a state of increased proliferative capacity and contribute to pulmonary artery wall remodeling.
• Furthermore, inhibition of HIF1a and disruption of microtubule structure with 2-methoxyestradiol may be an effective treatment to reduce or prevent pulmonary artery remodeling.
management/lookingafteryourdata/preservation/repositories) and in Table S1 . All studies on human tissue were approved by an institutional review committee, and studies conformed to local and national guidelines. Specific details on isolation of rat pulmonary artery smooth muscle cells (PASMCs) can also be found in Data S1.
Cellular Proliferation Experiments
Cellular proliferation was assessed manually using a hemocytometer or using the cell counting kit 8 (CCK8) assay (Dojindo; Kumamoto, Japan). See Data S1 for more details.
Caspase Activity
Caspase-3/7 activity was measured using the Cell Event assay (ThermoFisher; Runcorn, UK) and used according to manufacturer's instructions. See Data S1 for more details.
Immunoblotting
Protein expression was assessed by immunoblotting in whole lung tissue and hPASMCs. Details of antibodies used are shown in Table S2 .
Florescent Imaging
Cellular localiztion of a-tubulin in hPASMCs and rat PASMCs was assessed by immunofluorescence. See Data S1 for more details.
TaqMan Reverse Transcription Polymerase Chain Reaction mRNA transcripts from hPASMCs and rat whole lung tissue were assessed by quantitative reverse transcription polymerase chain reaction. Specific dual-labeled TaqMan primerprobe sets were purchased from ThermoFisher (Table S3) .
Histopathology
Saggital sections of lung (5 lm) were stained with elastinpicrosirius red. The number of remodeled vessels (as indicated by a double elastic lamina) per section were assessed in a blinded fashion. More details can be found in Data S1.
Statistical Analysis
All graphs and statistical analyses were produced and performed using Prism version 5 (GraphPad Software Inc; La Jolla, CA). All data are shown as meanAESEM and a P≤0.05 was considered statistically significant. Ratio data were log-transformed to ensure that they were normally distributed before employing parametric statistical analysis. For the comparison between vehicle and drug-treated cells, a paired t-test was employed, as cells from each patient were separated into 2 and cultured, so that cells from the same patient line were tested in the presence of vehicle and 2ME2. For comparison of 2 independent groups, a 2-tailed Student's unpaired t-test was used. For comparison of >2 groups, a 1-way ANOVA with Tukey's post hoc test was used. Statistical analysis used for each data set is indicated in the figure legend of each figure. Data are also displayed as fold change for interpretation purposes.
Results
Sex Differences in HIF1a Signaling
Basal protein expression of HIF1a was variable but significantly higher in female hPASMCs compared with males ( Figure 1A and 1B). There was increased basal PHD2 and FIH protein levels in male hPASMCs compared with female hPASMCs (Figure 1C and D) . mRNA transcript analysis revealed that there were no differences in HIF1a, PHD1, PHD2, PHD3, or Von Hippel-Lindau tumor suppressor levels between male and female hPASMCs ( Figure S1A through S1E). FIH mRNA levels were significantly lower in female hPASMCs ( Figure S1F ). Treatment with E2 (100 nmol/L; 72 hours) caused a significant decrease in FIH mRNA levels in both male and female hPASMCs compared with vehicle controls ( Figure S1G and S1H).
Effect of 2ME2 on Hemodynamic Measurements in the Chronic Hypoxic Model of PH
Chronic hypoxia caused a significant increase in RVSP, right ventricular hypertrophy, and pulmonary artery remodeling in both female and male rats ( Figure 2 ). 2ME2 reduced RVSP in female and male rats ( 
In Vivo Effects of 2ME2 on HIF1a Expression in the Chronic Hypoxic Model
Chronic hypoxia caused an increase in HIF1a protein expression in female rat whole lung tissue, which was subsequently reduced by 2ME2 ( Figure 3A and 3B). No changes in HIF1a mRNA levels were observed in whole lung tissue ( Figure 3C ). 2ME2 also reduced regional expression of HIF1a in the smooth muscle of distal pulmonary arteries in normoxia and hypoxia ( Figure 3D ). and male rats (B). Effects of 2ME2 on right ventricular hypertrophy in female (C) and male rats (D) and pulmonary artery remodeling with representative photomicrographs of lung sections stained with elastin-picrosirius red in female (E) and male rats (F). Data are shown as meanAESEM. All groups n=5; *P<0.05; **P<0.01; ***P<0.001 determined by 1-way ANOVA followed by Tukey's post hoc test. Scale bar indicates 70 lm. 2ME2 indicates 2-methoxyestradiol; Hx, hypoxic; Nx, normoxic; RVSP, right ventricular systolic pressure; Veh, vehicle.
Effects of 2ME2 on Cellular Proliferation in PASMCs
We investigated the role of 2ME2 (100 nmol/L-10 lmol/L) in the proliferative response of female hPASMCs. 2ME2 (10 lmol/ L, 48 hours) caused a significant decrease in cellular number in hPASMCs compared with vehicle control ( Figure 4A [cell counts] and B [CCK8 assay]). A significant reduction in proliferating cell nuclear antigen protein (PCNA) levels after 2ME2 (10 lmol/L, 48 hours) was also observed in female hPASMCs ( Figure 4C ). This reduction in proliferation by 2ME2 in hPASMCs was not abrogated by the estrogen receptor (ER)a antagonist MPP, the ERb antagonist PHTPP or the G protein-coupled estrogen receptor 1 antagonist G15 (all 100 nmol/L) ( Figure 4D ). 2ME2 also caused a significant reduction in the proliferative responses in isolated rat PASMCs after 48 hours ( Figure S2 ).
Effect of 2ME2 on HIF1a Protein Expression in hPASMCs
2ME2 (10 lmol/L, 48 hours) caused a significant reduction in HIF1a protein levels and downstream HK2 expression in hPASMCs ( Figure 5A and 5B, respectively).
Effects of 2ME2 on Expression of Proapoptotic and Antiproliferative Mediators
A significant increase in the proapoptotic Bcl-associated X mRNA transcript was observed in hPASMCs after treatment with 2ME2 (10 lmol/L, 48 hours) ( Figure 5C ). 2ME2 also caused an increase in the necroptotic mediator receptor-interacting serine/threonine-protein kinase 1 (RIPK1) in hPASMCs ( Figure 5D ). Furthermore, 2ME2 increased activated caspase 3/7 ( Figure 5E ). 2ME2 had no effect on caspase 9 or p53 mRNA transcript levels in hPASMCs or on bone morphogenetic protein receptor type II expression levels ( Figure S3 ).
Effects of Microtubule Disrupters and 2ME2 on Cellular Morphology and Cytoskeletal Network in PASMCs
2ME2 (10 lmol/L, 48 hours) caused significant changes in cellular morphology in hPASMCs with a decrease in cellular perimeter observed ( Figure S4 ). 2ME2 also caused disruption of the cytoskeletal a-tubulin network in both hPASMCs and rat PASMCs ( Figure 6A through D) and resulted in a significant reduction in a-tubulin protein levels in female hPASMCs ( Figure 6E ). 2ME2's effects on cellular morphology and tubulin structure were compared with Taxol and colchicine. Colchicine caused similar morphological changes in cellular structure ( Figure S5 ). However, colchicine appeared to be more potent than 2ME2 in disrupting the microtubule structure in female hPASMCs ( Figure S6 ).
Discussion
Here, for the first time, we have demonstrated differences in HIF1a signaling between male and female hPASMCs. We have also demonstrated the ability of 2ME2 to reverse hypoxiainduced PH in men and women and identified mechanisms by which 2ME2 may be protective in experimental PH. In the chronic hypoxic rat, we confirmed that 2ME2 caused a significant reduction in pulmonary artery remodeling, associated RVSP and right ventricular hypertrophy in both male and female rats. The most profound effect of 2ME2 was on the increased RVSP in hypoxia, which was completely reversed. This is not attributable to 2ME2-induced vasodilation, as it has been shown previously that 2ME2 is not vasoreactive in this regard. These data are consistent with the effects of 2ME2 in monocrotaline-and bleomycin-induced PH models. 9, 11, 12 2ME2 has been reported to be an HIF1a inhibitor, 23 so we examined the role of HIF1a in the in vivo effects of 2ME2. Following 2ME2 administration in vivo, we observed a significant reduction in HIF1a protein levels in the whole lung, suggesting that 2ME2 can reduce HIF1a expression. Indeed, 2ME2 has been shown to cause a reduction in the HIF1a/oxidative stress pathway in the chronic hypoxic rat model. 24 Similarly, we demonstrated that 2ME2 can inhibit
HIF1a in hPASMCs.
We demonstrated that female hPASMCs have higher basal levels of HIF1a protein than male hPASMCs, which may be a result of increased PHD2 expression within these cells. In addition, ERb can stabilize HIF1a in prostate cancer cell lines. 25 Either of these mechanisms may lead to increased HIF1a in female hPASMCs. Notably, however, female hPASMCs have significantly lower levels of the oxygendependent asparaginyl hydroxylase, FIH, a crucial inhibitor of the transactivational capacity of HIF1a. 26 To determine whether estrogen had any influence on FIH, we treated both male and female hPASMCs with estrogen and demonstrated that FIH mRNA levels decreased significantly. We chose to study the effects of estrogen, as it is the predominant female hormone that is known to act via estrogen receptors, whereas 2ME2 has little to no affinity for any of the estrogen receptors. Decreased FIH levels in females may increase the capacity of HIF1a to activate target genes in these cells. Furthermore, estrogen is likely to play a role in this activity through an as of yet unidentified pathway. We have shown previously that female hPASMCs are more proliferative than male hPASMCs when treated with promitogenic compounds such as serotonin (5-hydroxytryptamine). 5 Overall, increased basal levels of HIF1a and/or reduced inhibition of HIF1a may render female hPASMCs more susceptible to "second-hit" pro-proliferative mediators such as serotonin. Importantly, most of the cells used within this study were of postmenopausal age, as it was not possible to obtain PASMCs from younger donors; therefore, age and menopausal status cannot be ruled out as a potential factor in determining HIF1a expression and activity. As female hPASMCs have inherently higher levels of HIF1a and women are 4 times more likely to develop PAH, we chose to focus solely on female hPASMCs to determine what effect the molecular mechanisms of 2ME2 treatment may have on these cells. 2ME2 caused a significant reduction in proliferation in hPASMCs and female rat PASMCs. Indeed, this concentration range is consistent with previous findings in other cells types, and hPASMCs that have shown a significant reduction in cellular number after 2ME2 treatment. 11, 27 This antiproliferative effect was observed in the presence of estrogen receptor antagonists and suggests that 2ME2 is not acting through classical estrogen receptors to have its antiproliferative effect in hPASMCs. This is consistent with previous reports that 2ME2 has little or no affinity for estrogen receptors but does bind to tubulin. 28 Despite the fact that the receptors that mediate the biological effect of 2ME2 remain ill defined, it is reported to have numerous cardiovascular protective effects including inhibition of endothelin-1, production of prostacyclin, nitric oxide production, and antioxidant effects. 29 In addition, it has been proposed previously that 2ME2 may mediate some, but not all, of the antiproliferative effects of estrogen, effects that are independent of estrogen receptors. 29 The antiproliferative effects of estrogen are known to be mediated by both estrogen receptor-dependent and independent mechanisms. Indeed, we have shown previously that proliferation of hPASMCs can be mediated by the ERa receptor associated with mitogenactivated protein kinase and Akt signaling. 30 2ME2 induced a significant decrease in basal levels of HIF1a protein in non-PAH hPASMCs. A reduction in HIF1a levels may well lead to the less proliferative phenotype observed after treatment with 2ME2. Interestingly, 2ME2 caused a significant decrease in the downstream protein HK2 hPASMCs. HK2 is one of many welldefined HIF1a target genes and a crucial component of the glycolytic pathway. Metabolic switching to a more glycolytic phenotype in both experimental PH and PAH has been stated previously 18, 31, 32 ; therefore, assessing HK2 expression in our model was an important indicator of both the metabolic state and HIF1a activity within hPASMCs after 2ME2 treatment. Our data also suggest that 2ME2 may induce proapoptotic pathways as well as antiproliferative pathways in hPASMCs. 2ME2 induced an increase in the mitophagy-related Bclassociated X mRNA and the necroptotic related RIPK1 mRNA where RIPK1 allows the cell to undergo cell death in the absence of caspase activity. 33 Increases in Bcl-associated X expression with 2ME2 has been detailed previously in an epithelial cancer cell line. 34 Increased activity of caspase 3/7 provides further evidence for an apoptotic phenotype. These factors may well be central to the reduced cellular number observed in female hPASMCs in the presence of 2ME2. The apoptotic phenotype in PASMCs caused by 2ME2 may not be surprising on the basis of previous observations in other cell types. 27, 35, 36 We also observed a disruption of microtubules in both human and rat PASMCs; microtubule disruption has long been postulated to be a potential treatment in hyperproliferative cells. 37 There is also 42 This microtubule disruption may also contribute to the reduced perimeter and increased cellular size observed within the hPASMCs treated with 2ME2 as both a-and b-tubulin monomers are important for regulating cellular shape, motility, and division. 43 Interestingly, we also observed a reduction in a-tubulin protein levels in hPASMCs in the presence of 2ME2. It is unknown whether this is a negative feedback response in reaction to altered a-tubulin structure and dynamics. Previous studies in renal cells have noted a similar effect in response to the microtubule disruptors vincristine and dolastatin. 44 This study also showed that hPASMC microtubules were stabilized with taxol and disrupted with colchicine. Interestingly, a recent study has also demonstrated that colchicine was effective in reversing experimental PH by improving right ventricular function and pulmonary hemodynamics. 45 Taken together, this further suggests that microtubule disruption may be a potential therapeutic avenue in the treatment of pulmonary hypertension.
Conclusions
Estrogen is considered an important factor in female PAH patients, both before and after menopause, and men with PAH. Indeed, it has been shown recently that plasma estrogen levels are elevated in postmenopausal female PAH patients as well as men with idiopathic PAH. 46, 47 In addition, the levels of estrogen were associated with disease severity. Higher levels of HIF1a in female hPASMCs may make them more susceptible to promitogenic agents and subsequent pulmonary vascular remodeling. 2ME2 has multiple mechanisms of action that are cell and tissue specific. Here, we show that the antiproliferative effects of 2ME2 are not mediated through any of the estrogen receptors. In female hPASMCs, in vitro, 2ME2 lowers HIF1a protein expression and has both antiproliferative and proapoptotic properties. Furthermore, 2ME2 also causes significant microtubule dysruption which is likely to be the mechanism behind reduced HIF1a levels and the anti-proliferative effect of 2ME2 in these cells. In vivo, 2ME2 reversed hypoxia-induced PH and reduced lung HIF1a expression. These data suggest that disrupting microtubules and thereby inhibiting HIF1a may be a plausible translational target for PAH. Figure S7 summarizes our findings, suggesting a possible mechanism of action for 2ME2.
SUPPLEMENTAL MATERIAL
Data S1.
Expanded Materials and Methods
Animal studies
All experimental procedures were carried out in accordance with the United Kingdom Animal Procedures Act (1986) and with the "Guide for the Care and Use of Laboratory Animals" published by the US National Institutes of Health (NIH publication No. 85-23, revised 1996) and ethical approval was also granted by the University of Glasgow Ethics Committee. All in vivo studies and subsequent analysis were carried out blinded. There were two reasons for selecting the hypoxic rat model in this study. One was that we were focusing on the hypothesis that 2ME2 may exert its therapeutic effect via HIF1α and hence hypoxia on its own was the stimulus of choice. Secondly, we were interested in in vivo sex differences and many studies have shown that hypoxia-induced PH in rats is more severe in males than females and we wished to determine the effects of 2ME2 on these in vivo sex-dependent differences. Male and female Sprague Dawley rats weighing 200g were purchased from Envigo (Germany). Rodents were housed in a 12-hour light dark cycle with access to food and water ad libitum. For hypoxic studies, rats were placed in a hypobaric chamber for two weeks at an atmospheric pressure of 550 mbar after which they were removed for dosing. Animals were anaesthetised using 3% (v/v) isoflurane and a small incision was made in the scruff of the neck. A 3 mm slowrelease pellet containing either 2ME2 (1.26 mg pellet/21 days; 60ug/kg/day) (Abcam, UK/ Innovative research of America, USA) or vehicle carrier (Innovative research of America, USA) was implanted using a 10 gauge stainless steel precision trochar (MP-182; Innovative research of America, USA). The wound was then closed using medical grade glue (3M Vetbond, USA). Animals were allowed to recover fully before being placed back into hypobaric conditions for a further two weeks. Age and weight matched animals were also dosed in normoxic conditions for the control portion of the study using an identical procedure. No obvious irritation at implant site was observed for any animal in this study. Dosage of 2ME2 was based on previous published studies 1 .
Haemodynamic measurements
Animals were anaesthetically induced in 3% (v/v) isoflurane and then maintained at approximately 2% (v/v) isoflurane supplemented with a constant flow of medical oxygen (1L/min). Right ventricular systolic pressure (RVSP) measurements were taken using a Miller (UK) SPR-869 catheter and measurements recorded using the corresponding software (LabChart Pro). The catheter was inserted into the exposed right jugular vein and guided into the right ventricle of the heart to measure right ventricular pressure.
Right ventricular hypertrophy
In order to assess right ventricular hypertrophy the right ventricular (RV) free wall was removed and weighed. This was then expressed as a ratio to the left ventricular wall plus septum (LV+S) weight (RV/LV+S).
Culture and isolation of PASMCs
Female and male PASMCs were isolated from pulmonary arteries of patients undergoing a pneumonectomy procedure (0.3 -1 mm diameter) from distal portions of macroscopically normal lung tissue or from lungs of patients undergoing lung transplantation, as described previously. All human cells were isolated in Professor Nicholas Morrell's laboratory, Cambridge, UK. Experimental procedures using hPASMCs conform to the principles outlined in the declaration of Helsinki. All cells used within this study are detailed in Table S1 and were used between passages 4 and 8. Female rat PASMCs were isolated by enzymatic digestion of intra-lobar pulmonary arteries. Briefly, connective tissue/parenchyma/adventitia was removed from the pulmonary arteries. Under sterile conditions, the pulmonary arteries were washed with PBS, cut into smaller pieces and placed into enzymatic dissociation buffer pre-heated to 37°C (Ham's F-12 culture medium (Sigma, UK) containing 1% gentamycin, 1mg/ml type 1 collagenase, 0.125mg/ml elastase, 0.375mg/ml soybean trypsin inhibitor and 2mg/ml bovine serum albumin (Sigma, UK)). The tissue mixture was agitated gently at 37°C for 1-2 hours. Digestion mix was then passed through a 100 µm strainer and centrifuged at 1200 rpm for 3 minutes. The supernatant was removed and cells were re-suspended in fresh F12 medium (1% PenicillinStreptomycin, 10% FBS) for passage 0. At passages 1-4 cells were grown in 4.5g/l DMEM (1% Penicillin-Streptomycin, 10% FBS; Sigma, UK). Rat PASMCs were utilised for experiments between passages 2 and 4.
Cellular proliferation experiments
Cellular proliferation was assessed manually using a haemocytometer. Briefly, cells in 12-well dishes were grown to 50-60% confluency. Cells were then quiesced in 0.2% charcoal-striped serum (CSS) 2 for 24 hours. Media was then changed to 5% CSS and 2ME2 (Abcam, UK) or vehicle (ethanol) added to the well. After 48 hours cells were trypsinized and counted. Cellular proliferation/viability was also measured using the CCK-8 kit (Dojindo, Japan). Cells were grown in 96-well plates to 50% confluency then quiesced for 24 hours in 0.2% CSS. Cells were stimulated with 2ME2 or vehicle in 5% CSS. After for 46 hours the CCK-8 substrate was added to each well and incubated at 37°C for 2 hours. A plate reader was then used to measure the O.D. at 450nm.
Caspase activity assay
Cells were grown in 96-well culture dishes and stimulated for 6 hours. After 6 hours the media was removed and Cell Event reagent added for 30 mins. Fluorescent signal was then detected using a SpectraMax M2 plate reader with absorption/emission maxima of ~502/530 nm. Table S2 . In some instances blots were cut and probed for two separate antibodies. This was only carried out where proteins of interest exhibited a large difference in molecular weight and where antibodies have been validated and shown to be specific for their target. Blots where appropriate may be stripped and re-probed using loading controls.
Immunoblotting
Imaging
Cellular localisation of α-tubulin in hPASMCs was assessed by immunofluorescence.
Briefly, cells were grown on glass coverslips until 50-60% confluent. Cells were then washed in PBS and fixed in 4% paraformaldehyde (PFA) for 15 minutes at room temperature. Cells were then permeabilized with 0.2% Triton X-100/PBS (Sigma, UK) and blocked with 2%BSA/PBS with 0.05% Tween-20 (Sigma, UK). α-tubulin primary antibody (1:500; Sigma, UK) was added to the coverslips and incubated overnight at 4ºC. Cells were then washed in PBS and incubated with secondary antibody for 1 hour at room temperature (Alexa goat anti-mouse 594, ThermoFisher Scientific, UK). After a further PBS wash, ProLong™ Diamond antifade mountant with DAPI (ThermoFisher Scientific, UK) was applied to the coverslips and mounted on glass slides for imaging. Images were acquired using an LSM-510 or LSM-800 laser-scanning confocal microscope (Zeiss, Germany). Brightfield images were captured using an EVOS XL core microscope (ThermoFisher Scientific). All subsequent cellular measurements were performed using ImageJ (NIH) software.
TaqMan™ RT-PCR
RNA was extracted by finely mincing tissue with a scalpel then placing into QIAzol solution (Qiagen, UK). Tissue was then lysed using a Qiagen Tissue lyser and RNA was extracted with miRNeasy® mini kit following the manufacturers protocol (Qiagen, UK). Cells were scraped and also lysed using QIAzol solution. RNA was quantified using a nanodrop (ND-1000 spectrophotometer (Thermo-Fisher, UK) and normalised to approximately 300ng total RNA. RNA was then reverse transcribed to cDNA using the TaqMan™ reverse transcription kit (Applied Biosystems). Semiquantitative real-time PCR was performed using an Applied Biosystems Viia 7 realtime PCR system. Specific dual labelled TaqMan™ primer-probe sets were purchased from Thermo-Fisher, UK (Table S3) . Results are expressed as a ratio to a reference gene using the 2 -ΔCt comparison method or as fold change when comparing drug treatments. 
Effect of 2ME2 (100nm-10µM) on FBS-induced proliferation in isolated rat female
PASMCs assessed by manual cell counts (A) and CCK8 assay (B) after 48 hours (n=5 and 4, respectively). Data is shown as mean ±SEM.  p<0.05;   p<0.01;    p< 0.001 determined by one way ANOVA followed by Tukey's post-hoc test.
Veh, vehicle. 
